Phylo puts Biomni Lab into Bayer's drug-discovery evidence workflow
Phylo CEO Kexin Huang's Stanford research project has grown into an enterprise platform Bayer will use to assemble literature and omics evidence for drug discovery.
By RuntimeWire Staff · Published
Primary source: PR Newswire
Why it matters
The agreement puts Biomni Lab into Bayer's drug-discovery evidence workflows, giving Phylo a test of adoption inside pharma.
Kexin Huang (@KexinHuang5) built Biomni around a question: could an AI agent do the scientific legwork that slows researchers down while showing them how it reached its conclusions? On October 22nd, Phylo, the company he co-founded, said Bayer would deploy Biomni Lab for drug-discovery workflows focused on assembling scientific literature and omics evidence. The agreement brings Huang's research thesis into a major pharmaceutical R&D organization.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.